W
Wenfeng Fang
Researcher at Sun Yat-sen University
Publications - 233
Citations - 6222
Wenfeng Fang is an academic researcher from Sun Yat-sen University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 33, co-authored 175 publications receiving 3993 citations. Previous affiliations of Wenfeng Fang include Wuhan University & University of Illinois at Chicago.
Papers
More filters
Journal ArticleDOI
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
Nan Chen,Wenfeng Fang,Jianhua Zhan,Shaodong Hong,Yanna Tang,Shiyang Kang,Yaxiong Zhang,Xiaobo He,Ting Zhou,Tao Qin,Yan Huang,Xianping Yi,Li Zhang +12 more
TL;DR: The results imply that EGFR-TKIs could not only directly inhibit tumor cell viability but also indirectly enhance antitumor immunity through the downregulation of PD-L1.
Journal ArticleDOI
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
Wenfeng Fang,Yunpeng Yang,Yuxiang Ma,Shaodong Hong,Lizhu Lin,Xiaohui He,Jianping Xiong,Ping Li,Hongyun Zhao,Yan Huang,Yang Zhang,Likun Chen,Ningning Zhou,Yuanyuan Zhao,Xue Hou,Qing Yang,Li Zhang +16 more
TL;DR: This work presents safety and preliminary antitumour activity of camrelizumab alone as second-line therapy in patients with recurrent or metastatic nasopharyngeal carcinoma and combined with gemcitabine and cisplatin as first-line Therapy in this patient population.
Journal ArticleDOI
EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
Wenfeng Fang,Jianwei Zhang,Shaodong Hong,Jianhua Zhan,Nan Chen,Tao Qin,Yanna Tang,Yaxiong Zhang,Shiyang Kang,Ting Zhou,Xuan Wu,Wenhua Liang,Zhihuang Hu,Yuxiang Ma,Yuanyuan Zhao,Ying Tian,Yunpeng Yang,Cong Xue,Yue Yan,Xue Hou,Pei Yu Huang,Yan Huang,Hongyun Zhao,Li Zhang +23 more
TL;DR: It is found that EBV-induced latent membrane protein 1 (LMP1) and IFN-γ pathways cooperate to regulate programmed cell death protein 1 ligand (PD-L1), which was higher in EBV positive NPC cell lines compared with EBV negative cell lines.
Journal ArticleDOI
The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
Yanna Tang,Wenfeng Fang,Yaxiong Zhang,Shaodong Hong,Shiyang Kang,Yue Yan,Nan Chen,Jianhua Zhan,Xiaobo He,Tao Qin,Ge Li,Wenyi Tang,Peijian Peng,Li Zhang +13 more
TL;DR: High PD-L1 expression was likely to be associated with the presence of EGFR mutation in advanced lung adenocarcinoma, and this can be considered as a poor prognostic indicator of OS for EGFR wild-type patients.
Journal ArticleDOI
KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma
Nan Chen,Wenfeng Fang,Zhong Lin,Peijian Peng,Juan Wang,Jianhua Zhan,Shaodong Hong,Jiaxing Huang,Lin Liu,Jin Sheng,Ting Zhou,Ying Chen,Hong-Yu Zhang,Li Zhang +13 more
TL;DR: It is demonstrated that KRAS mutation could induce PD-L1 expression through p-ERK signaling in lung adenocarcinoma and blockade of PD-1/PD- L1 pathway may be a promising therapeutic strategy for human KRAS-mutant lungAdenocARCinoma.